181 related articles for article (PubMed ID: 1937767)
1. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.
Hartman AB; Powell CJ; Schultz CL; Oaks EV; Eckels KH
Infect Immun; 1991 Nov; 59(11):4075-83. PubMed ID: 1937767
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.
Barry EM; Wang J; Wu T; Davis T; Levine MM
Vaccine; 2006 May; 24(18):3727-34. PubMed ID: 16169130
[TBL] [Abstract][Full Text] [Related]
3. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.
Noriega FR; Losonsky G; Wang JY; Formal SB; Levine MM
Infect Immun; 1996 Jan; 64(1):23-7. PubMed ID: 8557344
[TBL] [Abstract][Full Text] [Related]
4. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
[TBL] [Abstract][Full Text] [Related]
5. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.
Koprowski H; Levine MM; Anderson RJ; Losonsky G; Pizza M; Barry EM
Infect Immun; 2000 Sep; 68(9):4884-92. PubMed ID: 10948101
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
[TBL] [Abstract][Full Text] [Related]
7. Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.
Hartman AB; Venkatesan MM
Infect Immun; 1998 Sep; 66(9):4572-6. PubMed ID: 9712824
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.
Kotloff KL; Herrington DA; Hale TL; Newland JW; Van De Verg L; Cogan JP; Snoy PJ; Sadoff JC; Formal SB; Levine MM
Infect Immun; 1992 Jun; 60(6):2218-24. PubMed ID: 1587589
[TBL] [Abstract][Full Text] [Related]
9. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine.
Oaks EV; Turbyfill KR
Vaccine; 2006 Mar; 24(13):2290-301. PubMed ID: 16364513
[TBL] [Abstract][Full Text] [Related]
10. [Construction of prophylactic recombinant HPV58-attenuated Shigella vector live vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model].
Li WS; Liu HL; Zhang YT; Yang XF; Wang YL; Si LS
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1163-6. PubMed ID: 18062891
[TBL] [Abstract][Full Text] [Related]
11. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.
Hartman AB; Van de Verg LL; Collins HH; Tang DB; Bendiuk NO; Taylor DN; Powell CJ
Infect Immun; 1994 Feb; 62(2):412-20. PubMed ID: 7507892
[TBL] [Abstract][Full Text] [Related]
12. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines.
Hartman AB; Van De Verg LL; Venkatesan MM
Infect Immun; 1999 Nov; 67(11):5841-7. PubMed ID: 10531238
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
Orr N; Robin G; Cohen D; Arnon R; Lowell GH
Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
[TBL] [Abstract][Full Text] [Related]
14. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine.
Venkatesan MM; Hartman AB; Newland JW; Ivanova VS; Hale TL; McDonough M; Butterton J
Infect Immun; 2002 Jun; 70(6):2950-8. PubMed ID: 12010984
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.
Ranallo RT; Thakkar S; Chen Q; Venkatesan MM
Vaccine; 2007 Mar; 25(12):2269-78. PubMed ID: 17229494
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.
Noriega FR; Wang JY; Losonsky G; Maneval DR; Hone DM; Levine MM
Infect Immun; 1994 Nov; 62(11):5168-72. PubMed ID: 7927802
[TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of virG (icsA)-deleted Escherichia coli K12-Shigella flexneri hybrid vaccine strains.
Alexander WA; Hartman AB; Oaks EV; Venkatesan MM
Vaccine; 1996 Aug; 14(11):1053-61. PubMed ID: 8879102
[TBL] [Abstract][Full Text] [Related]
18. Shigella flexneri 2a and sonnei I vaccine with two attenuating markers: construction, tolerability and immunogenicity in 143 children aged 3-17 years.
Linde K; Randhagen B; Beer J; Dentchev V; Marinova S; Vassilev T; Bratoyeva M
Vaccine; 1993; 11(2):197-9. PubMed ID: 8438618
[TBL] [Abstract][Full Text] [Related]
19. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.
Ranallo RT; Fonseka S; Boren TL; Bedford LA; Kaminski RW; Thakkar S; Venkatesan MM
Vaccine; 2012 Jul; 30(34):5159-71. PubMed ID: 22658966
[TBL] [Abstract][Full Text] [Related]
20. Development of an auxotrophic oral live Shigella flexneri vaccine.
Lindberg AA; Kärnell A; Stocker BA; Katakura S; Sweiha H; Reinholt FP
Vaccine; 1988 Apr; 6(2):146-50. PubMed ID: 2838986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
